profile

Oncology Hero

Regeneron Buys 23andMe Assets, Cholangioscopy Boosts Bile Duct Cancer Diagnosis

Published 5 months ago • 1 min read

​

​

Regeneron Acquires 23andMe Research Division for $256M in Bankruptcy Auction

Context: As 23andMe navigates Chapter 11 proceedings, key assets tied to its vast genomic database and pharma partnerships have drawn industry attention.

What's New? Regeneron has secured a $256 million deal to acquire 23andMe’s therapeutics subsidiary, aiming to leverage the platform’s extensive genotypic and phenotypic data to fuel its precision medicine pipeline.

Why it Matters? This acquisition gives Regeneron a unique genomic asset to power AI-driven drug discovery, reinforce existing target validation strategies, and accelerate translational efforts across its R&D engine.

​Read More​

Cholangioscopy Use Linked to Better Bile Duct Cancer Diagnosis

Context: Cholangiocarcinoma is often diagnosed late due to subtle symptoms and low-yield imaging or sampling techniques.

What's New? A new study shows that the integration of cholangioscopy significantly improved diagnostic yield in patients with suspected bile duct cancer, compared with traditional ERCP-guided biopsies alone.

Why it Matters? Enhanced diagnostic precision may enable earlier detection and better treatment planning, particularly in perihilar and intrahepatic cases where therapeutic options remain limited.

​Read More​

Zepzelca Adds Survival Benefit in SCLC But Clinical Impact Modest

Context: Small cell lung cancer (SCLC) remains an aggressive disease with limited treatment advances over decades.

What's New? Roche and Jazz Pharmaceuticals presented ASCO data showing that adding Zepzelca (lurbinectedin) to standard chemotherapy produced a modest improvement in overall survival in previously untreated ES-SCLC patients, but raised toxicity concerns.

Why it Matters? While the result represents a small step forward, the data reinforce the need for novel, better-tolerated strategies in this underserved population.

​Read More​

Researchers Identify Key Regulator of Bone Metastasis in Solid Tumors

Context: Bone metastasis is a major complication in breast, prostate, and lung cancers, often leading to skeletal events and poor outcomes.

What's New? Scientists have pinpointed a transcriptional regulator called MAF that drives bone metastasis via osteoclast signaling and cellular adhesion pathways, offering a potential druggable node to interrupt metastatic spread.

Why it Matters? This discovery opens the door to targeted therapies aimed at halting bone-tropic cancers before they cause irreversible skeletal damage, potentially transforming metastatic care strategies.

​Read More​

​

Oncology Hero

Sharing the latest updates in oncology

Read more from Oncology Hero

In partnership with Oncology Updates — Aug 26 to Sep 2025 September delivered practice-relevant oncology updates worldwide — guideline shifts, pivotal trial readouts, new approvals, and high-impact AI tools. Below is a concise, clinician-first roundup. 🎗️ 🩺Lung cancer ESMO issues NSCLC guideline for early & locally advanced disease New recommendations standardize biomarker-driven multimodality care in stage I–III NSCLC, including integration of IO/targeted therapy in pathways. Read more...

24 days ago • 3 min read

Oncology Updates — August 2025 August 2025 delivered practice-relevant oncology updates worldwide — fresh guideline shifts, pivotal trial readouts, new approvals, diagnostics/devices, and high-impact AI tools. Below is a concise, clinician-first roundup, capped with a focused deep dive on the updated ASCO NSCLC guidelines. 🎗️ 💼 Earn for training the next generation of AI tools Medical Expert Hourly contract · Remote · $130–$180 per hour Apply here Physicians, Pathologists (Health Care and...

about 2 months ago • 2 min read

Cullinan and Taiho Reveal Positive NSCLC Data Ahead of FDA Filing Context: Cullinan Oncology and Taiho are developing CLN-081, an EGFR exon 20 insertion–targeting therapy for NSCLC—a mutation subtype with limited approved options. What's New? At ASCO, the companies presented data showing a response rate of 41% and a 12.7-month median duration of response for CLN-081. The results are expected to support an FDA submission in the second half of 2024. Why it Matters? These findings position...

5 months ago • 1 min read